| Ytd | -30.81% | |
| 1y | -46.66% |
| Open | 0.52 | Prev Close | 0.52 | Low | 0.48 | High | 0.53 | Mkt Cap | 5.38M |
| Vol | 105.52K | Avg Vol | 110.53K | EPS | -2.77 | P/E | N/A | Forward P/E | -4.21 |
| Beta | -0.20 | Short Ratio | 1.09 | Inst. Own | 13.16% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 0.63 | 200-d Avg | 0.74 | 1yr Est | 0.00 |
PMCB News
Nuvilex Inc. (NASDAQ: PMCB - Get Free Report) shares traded up 5.3% on Monday. The stock traded as h
On December 1, 2025, PharmaCyte Biotech, Inc. (the "Company") received a written notice (th
Avadel Pharmaceuticals (NASDAQ: AVDL - Get Free Report) and Nuvilex (NASDAQ: PMCB - Get Free Report)
PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte" or the "Company"), today announ
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”),
PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly losses of $(1.23) per share. This is a 164.74 pe
TNF new strategic partner LightSolver named a 2025 World Economic Forum Technology Pioneer and recog
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”),
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”) a
PharmaCyte Biotech (NASDAQ:PMCB) reported quarterly earnings of $1.54 per share. This is a 566.67 pe
Second external investment in life sciences solidifies previously announced strategy to utilize sign
BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Com
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”),
New investment marks expansion of corporate strategy to utilize significant cash position to create
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”)
Company prepares for comprehensive discussion with FDA to determine appropriate next steps for techn
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”)
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”)
On Monday, 369 companies set new 52-week lows.
On Tuesday, 386 stocks made new 52-week lows.
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”)
Federal Funding Increases Fuel Research Progress and Help Improve Patient OutcomesLOS ANGELES, June
Concurrently, the Company Announces $35 Million Financing of Convertible Preferred Stock at $4.00 pe
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”)
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”)
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”),
LAS VEGAS--( BUSINESS WIRE )--PharmaCyte Biotech, Inc. (Nasdaq:PMCB) (“PharmaCyte” or the “Company”)
LAS VEGAS, Oct. 07, 2022 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (NASDAQ:PMCB) ("PharmaCyte
Topics to Include Continued Analysis of FDA's Clinical Hold on IND for Cell-in-a-Box® Topics to Incl
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte and Iroquois have reached a settlement which includes appoint
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused
https://pharmacyte.com/pharmacyte-biotech-rebukes-iroquois-commencement-of-consent-solicitation/